Ventyx Biosciences, Inc. announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models. Two separate 28-day studies were conducted with VTX3232 in DIO mice. In DIO Study 1, VTX3232 and semaglutide were evaluated as monotherapies compared to standard diet and DIO vehicle (high fat diet) controls.

DIO Study 2 included an additional treatment group evaluating VTX3232 in combination with semaglutide. Key findings are summarized below. DIO Study 1 (VTX3232 monotherapy): Treatment with VTX3232 resulted in decreased body weight and food intake compared to DIO control.

Reductions in liver steatosis and triglycerides were also observed. Improvements in cardiometabolic parameters were observed with VTX3232, including reductions in cholesterol, insulin resistance, fasting blood glucose and HbA1c. Systemic inflammatory biomarkers, including IL-1ß, IL-6, and fibrinogen, were reduced in the plasma of VTX3232-treated DIO mice.

DIO Study 2 (VTX3232 in combination with semaglutide): The combination of VTX3232 and semaglutide resulted in greater benefit on body weight, liver steatosis and metabolic parameters compared to VTX3232 or semaglutide alone. Systemic inflammatory biomarkers, including IL-1ß, IL-6, and fibrinogen, were further reduced in the combination arm relative to DIO mice dosed with VTX3232 or semaglutide alone. A clear trend towards improved body composition was observed with VTX3232 + semaglutide combination therapy, including a decrease in fat mass and a corresponding increase in lean mass as a percentage of total body weight.

The Company intends to submit the comprehensive results of these studies for future publication or presentation in a scientific forum.